Movement Disorders (revue) - Exploration (Accueil)

Index « Mesh.i » - entrée « Clinical Trials as Topic »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Clinical Protocols < Clinical Trials as Topic < Clinical Trials, Phase II as Topic  Facettes :

List of bibliographic references indexed by Clinical Trials as Topic

Number of relevant bibliographic references: 70.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000192 (2015) C Warren Olanow [États-Unis]Levodopa: effect on cell death and the natural history of Parkinson's disease.
000406 (2014) Edward J. Wild ; Sarah J. TabriziTargets for future clinical trials in Huntington's disease: What's in the pipeline?
000413 (2014) Tiago A. Mestre [Canada] ; Alberto J. Espay ; Connie Marras ; Mark H. Eckman ; Pierre Pollak ; Anthony E. LangSubthalamic nucleus-deep brain stimulation for early motor complications in Parkinson's disease-the EARLYSTIM trial: early is not always better.
000527 (2014) Elizabeth H. AylwardMRI Striatal Volumes – A Biomarker for Clinical Trials in HD
000639 (2014) Cristina Sampaio [États-Unis] ; Beth Borowsky ; Ralf ReilmannClinical trials in Huntington's disease: Interventions in early clinical development and newer methodological approaches.
000714 (2013) Anthony E. Lang [Canada] ; Eldad Melamed ; Werner Poewe [Autriche] ; Olivier RascolTrial designs used to study neuroprotective therapy in Parkinson's disease.
000845 (2013) Ralf Reilmann [Allemagne]Pharmacological treatment of chorea in Huntington’s disease–good clinical practice versus evidence-based guideline
000873 (2013) Fabrizio Stocchi [Italie] ; C Warren OlanowObstacles to the development of a neuroprotective therapy for Parkinson's disease.
000971 (2013) Uriel Heresco-Levy [Israël] ; Shai Shoham ; Daniel C. JavittGlycine site agonists of the N-methyl-D-aspartate receptor and Parkinson's disease: a hypothesis.
000A76 (2013) Anders Bjorklund [Suède] ; Jeffrey H. KordowerCell therapy for Parkinson's disease: what next?
000B72 (2012) C Warren Olanow [États-Unis] ; José A. ObesoThe significance of defining preclinical or prodromal Parkinson's disease.
000C54 (2012) Johannes R. Streffer [Belgique] ; Igor D. Grachev ; Cheryl Fitzer-Attas ; Baltazar Gomez-Mancilla ; Babak Boroojerdi ; Juliana Bronzova ; Susanne Ostrowitzki ; Stephen J. Victor ; Paulo Fontoura ; Robert AlexanderPrerequisites to launch neuroprotective trials in Parkinson's disease: an industry perspective.
000C59 (2012) Esther Cubo [Espagne] ; Miguel González ; Inés Del Puerto ; Justo Garcia De Yébenes ; Olga Fernández Arconada ; José María Trejo Gabriel Y GalánPlacebo effect characteristics observed in a single, international, longitudinal study in Huntington's disease.
000C80 (2012) Todd B. Sherer [États-Unis] ; Sohini Chowdhury ; Katherine Peabody ; Deborah W. BrooksOvercoming obstacles in Parkinson's disease.
000F86 (2012) Scott Y. H. Kim [États-Unis] ; Raymond De Vries [États-Unis] ; Robert G. Holloway [États-Unis] ; Renee Wilson [États-Unis] ; Sonali Parnami [États-Unis] ; H. Myra Kim [États-Unis] ; Samuel Frank [États-Unis] ; Karl Kieburtz [États-Unis]Sham Surgery Controls in Parkinson's Disease Clinical Trials: Views of Participants
001433 (2011) Norman C. Reynolds Jr. [États-Unis] ; Robert B. Slocum [États-Unis]Rational therapy: A defense against evidence‐based medicine
001459 (2011) Connie Marras [Canada] ; Michael P. Mcdermott [États-Unis] ; Ken Marek [États-Unis] ; Paula Rochon [Canada] ; Gary Naglie [Canada] ; Caroline M. Tanner [États-Unis] ; Alice Rudolph [États-Unis] ; Ira Shoulson [États-Unis] ; Anthony E. Lang [Canada]Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts
001554 (2011) C. Warren Olanow [États-Unis] ; Kathryn B. Wunderle [États-Unis] ; Karl Kieburtz [États-Unis]Milestones in movement disorders clinical trials: Advances and landmark studies
001565 (2011) Rebecca Stowe [Royaume-Uni] ; Natalie Ives [Royaume-Uni] ; Carl E. Clarke [Royaume-Uni] ; Kelly Handley [Royaume-Uni] ; Alexandra Furmston [Royaume-Uni] ; Katherine Deane [Royaume-Uni] ; J. J. Van Hilten [Pays-Bas] ; Keith Wheatley [Royaume-Uni] ; Richard Gray [Royaume-Uni]Meta‐analysis of the comparative efficacy and safety of adjuvant treatment to levodopa in later Parkinson's disease
001641 (2011) Tiago Teodoro [Portugal] ; Daniela Pires [Portugal] ; Mário M. Rosa [Portugal] ; Miguel Coelho [Portugal] ; Cristina Sampaio [Portugal] ; Joaquim J. Ferreira [Portugal]Has “levodopa‐induced neuropathy” been reported in Parkinson's disease clinical trials?
001667 (2011) Peter Jenner [Royaume-Uni] ; J. William Langston [États-Unis]Explaining ADAGIO: A critical review of the biological basis for the clinical effects of rasagiline

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i -k "Clinical Trials as Topic" 
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/Mesh.i  \
                -Sk "Clinical Trials as Topic" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Main
   |étape=   Exploration
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Clinical Trials as Topic
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024